⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary Figure S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma

Paolo Strati Lei Feng Andrey Tyshevich Darya Shavronskaya Julia Alesse Noel English Elizabeth Sheehan Nikita Syzrantsev Alexander Nesmelov Tony Zhuang Dai Chihara Jason R. Westin Sairah Ahmed Luis Fayad Jared Henderson Karin M. Dent Elizabeth McChesney Sattva S. Neelapu Christopher R. Flowers

View Full Paper

Ask AI

Bookmark

Share

Key Points

Laboratory trends reveal important data during treatment with evorpacept, lenalidomide, and rituximab for B-cell non-Hodgkin lymphoma.
In this phase I trial, patients experienced notable laboratory changes, influencing treatment decisions.
Utilizing observational analysis during therapy for B-cell non-Hodgkin lymphoma, this research highlights evolving health metrics.
The findings underline the potential of laboratory trends in adjusting treatment strategies for lymphoma patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I trial explores laboratory trends in patients with B-cell non-Hodgkin lymphoma, indicating treatment impact.

Abstract

Laboratory trends during treatment

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strati et al. (2025) studied this question.

synapsesocial.com/papers/68e040f7a99c246f578b3bf9 https://doi.org/10.1158/1078-0432.30255122

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
2Supplementary Figure S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
3Supplementary Figure S4 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
4Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
5Data from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025